RAPT Therapeutics Inc
RAPT12.280USD
+0.580+4.96%
收盤 07/22, 16:00（美東）報價延遲15分鐘
202.63M總市值
虧損本益比TTM
關於 RAPT Therapeutics Inc 公司
RAPT Therapeutics, Inc. 是一家臨牀階段的免疫學生物製藥公司。該公司專注於發現、開發和商業化口服小分子療法，以滿足炎症疾病和腫瘤學領域中尚未得到滿足的大量需求。該公司利用其藥物發現和開發引擎，開發旨在調節這些疾病背後的關鍵免疫反應的選擇性小分子。其領先的炎症候選藥物 zelnecirnon (RPT193) 和其領先的腫瘤候選藥物 tivumecirnon (FLX475) 均靶向 CC 基序趨化因子受體 4 (CCR4)，這是一種可能在炎症疾病和腫瘤學中具有廣泛適用性的藥物靶點。其炎症候選藥物 zelnecirnon 旨在選擇性抑制 2 型 T 輔助細胞向炎症組織的遷移。其腫瘤候選藥物 tivumecirnon 旨在選擇性抑制免疫抑制調節性 T 細胞向腫瘤的遷移。
公司簡介
公司代碼RAPT
公司名稱RAPT Therapeutics Inc
上市日期Oct 31, 2019
成立日期2015
CEODr. Brian Wong, M.D., Ph.D.
員工數量68
證券類型Ordinary Share
年結日Oct 31
公司地址561 Eccles Ave
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編94080
電話16504899000
網址https://rapt.com/
公司代碼RAPT
上市日期Oct 31, 2019
成立日期2015
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Dr. Ashley Dombkowski, Ph.D.
Dr. Ashley Dombkowski, Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
--
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
--
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Linda Kozick
Ms. Linda Kozick
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Dr. Ashley Dombkowski, Ph.D.
Dr. Ashley Dombkowski, Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
--
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
--
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Medicxi Ventures (UK) LLP
16.90%
OrbiMed Advisors, LLC
9.93%
TCG Crossover Management, LLC
9.90%
Foresite Capital Management, LLC
9.45%
RTW Investments L.P.
8.89%
Other
44.94%
持股股東
持股股東
佔比
Medicxi Ventures (UK) LLP
16.90%
OrbiMed Advisors, LLC
9.93%
TCG Crossover Management, LLC
9.90%
Foresite Capital Management, LLC
9.45%
RTW Investments L.P.
8.89%
Other
44.94%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
23.19%
Private Equity
22.72%
Hedge Fund
21.09%
Venture Capital
17.98%
Investment Advisor
13.34%
Research Firm
0.60%
Individual Investor
0.44%
Bank and Trust
0.09%
Family Office
0.09%
Other
0.46%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
295
16.51M
99.85%
-973.81K
2025Q1
309
29.14M
109.47%
+11.54M
2024Q4
309
140.52M
106.54%
+100.36M
2024Q3
304
31.22M
87.82%
-13.95M
2024Q2
305
33.18M
93.85%
-9.52M
2024Q1
295
33.76M
95.60%
-5.47M
2023Q4
282
36.46M
106.02%
-3.53M
2023Q3
281
36.40M
105.98%
-3.26M
2023Q2
295
35.63M
103.77%
-4.21M
2023Q1
301
34.71M
101.29%
-3.14M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Medicxi Ventures (UK) LLP
2.79M
16.9%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
1.64M
9.93%
--
--
Mar 31, 2025
TCG Crossover Management, LLC
1.64M
9.9%
-5.63K
-0.34%
Mar 31, 2025
Foresite Capital Management, LLC
1.56M
9.45%
--
--
Mar 31, 2025
RTW Investments L.P.
1.47M
8.89%
--
--
Mar 31, 2025
BVF Partners L.P.
1.15M
6.98%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.03M
6.26%
+668.30K
+182.32%
Mar 31, 2025
Redmile Group, LLC
809.41K
4.89%
--
--
Mar 31, 2025
Deep Track Capital LP
751.42K
4.54%
--
--
Mar 31, 2025
Adar1 Capital Management LLC
746.35K
4.51%
+599.56K
+408.45%
Mar 31, 2025
查看更多
持股ETF
更新時間: 7月6日 週日
更新時間: 7月6日 週日
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
ProShares UltraPro Russell2000
0%
Nuveen ESG Small-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
Humankind US Stock ETF
0%
Invesco Dorsey Wright Healthcare Momentum ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Proshares Ultra Russell 2000
0%
SPDR S&P Biotech ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0%
Nuveen ESG Small-Cap ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
Humankind US Stock ETF
佔比0%
Invesco Dorsey Wright Healthcare Momentum ETF
佔比0%
Invesco Nasdaq Biotechnology ETF
佔比0%
ProShares Ultra Nasdaq Biotechnology
佔比0%
Proshares Ultra Russell 2000
佔比0%
SPDR S&P Biotech ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
